Gene-dosage- and Sex-dependent Differences in the Prodromal-Like Phase of the F344tgHD Rat Model for Huntington Disease

Overview

Journal Front Neurosci

Date 2024 Feb 22

PMID 38384482

Authors

Veronika Ratz-Wirsching

Johanna Habermeyer

Sandra Moceri

Julia Harrer

Christoph Schmitz

Stephan von Horsten

Affiliations

Soon will be listed here.

Abstract

In Huntington disease (HD) the prodromal phase has been increasingly investigated and is currently in focus for early interventional treatments. Also, the influence of sex on disease progression and severity in patients is under discussion, as a sex-specific impact has been reported in transgenic rodent models for HD. To this end, we have been studying these aspects in Sprague Dawley rats transgenic for HD. Here, we took up on the congenic F344tgHD rat model, expressing a fragmented construct with 51 CAG repeats on an inbred F344 rat background and characterized potential sexual dimorphism and gene-dosage effects in rats during the pre-symptomatic phase (1-8 months of age). Our study comprises a longitudinal phenotyping of motor function, emotion and sensorimotor gating, as well as screening of metabolic parameters with classical and automated assays in combination with investigation of molecular HD hallmarks (striatal cell number and volume estimation, appearance of HTT aggregates). Differences between sexes became apparent during middle age, particularly in the motor and sensorimotor domains. Female individuals were generally more active, demonstrated different gait characteristics than males and less anxiolytic-like behavior. Alterations in both the time course and affected behavioral domains varied between male and female F344tgHD rats. First subtle behavioral anomalies were detected in transgenic F344tgHD rats prior to striatal MSN cell loss, revealing a prodromal-like phase in this model. Our findings demonstrate that the congenic F344tgHD rat model shows high face-validity, closely resembling the human disease's temporal progression, while having a relatively low number of CAG repeats, a slowly progressing pathology with a prodromal-like phase and a comparatively subtle phenotype. By differentiating the sexes regarding HD-related changes and characterizing the prodromal-like phase in this model, these findings provide a foundation for future treatment studies.

Citing Articles

Circadian Interventions in Preclinical Models of Huntington's Disease: A Narrative Review.

DellAngelica D, Singh K, Colwell C, Ghiani C Biomedicines. 2024; 12(8).

PMID: 39200241 PMC: 11351982. DOI: 10.3390/biomedicines12081777.

References

Bode F, Stephan M, Suhling H, Pabst R, Straub R, Raber K . Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet. 2008; 17(17):2595-609. DOI: 10.1093/hmg/ddn159. View

File S, Seth P . A review of 25 years of the social interaction test. Eur J Pharmacol. 2003; 463(1-3):35-53. DOI: 10.1016/s0014-2999(03)01273-1. View

Konig C, Plank A, Kapp A, Timotius I, von Horsten S, Zimmermann K . Thirty Mouse Strain Survey of Voluntary Physical Activity and Energy Expenditure: Influence of Strain, Sex and Day-Night Variation. Front Neurosci. 2020; 14:531. PMC: 7358574. DOI: 10.3389/fnins.2020.00531. View

Gassner H, Jensen D, Marxreiter F, Kletsch A, Bohlen S, Schubert R . Gait variability as digital biomarker of disease severity in Huntington's disease. J Neurol. 2020; 267(6):1594-1601. PMC: 7293689. DOI: 10.1007/s00415-020-09725-3. View

Cao C, Temel Y, Blokland A, Ozen H, Steinbusch H, Vlamings R . Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington's disease transgenic ratmodel. Behav Brain Res. 2006; 170(2):257-61. DOI: 10.1016/j.bbr.2006.02.028. View

Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R . Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 1997; 90(3):549-58. DOI: 10.1016/s0092-8674(00)80514-0. View

Kuemmerle S, Gutekunst C, Klein A, Li X, Li S, Beal M . Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol. 1999; 46(6):842-9. View

Meoni S, Macerollo A, Moro E . Sex differences in movement disorders. Nat Rev Neurol. 2020; 16(2):84-96. DOI: 10.1038/s41582-019-0294-x. View

Zielonka D, Marinus J, Roos R, De Michele G, Di Donato S, Putter H . The influence of gender on phenotype and disease progression in patients with Huntington's disease. Parkinsonism Relat Disord. 2012; 19(2):192-7. DOI: 10.1016/j.parkreldis.2012.09.012. View

10.

Halliday G, McRitchie D, MacDonald V, Double K, Trent R, McCusker E . Regional specificity of brain atrophy in Huntington's disease. Exp Neurol. 1999; 154(2):663-72. DOI: 10.1006/exnr.1998.6919. View

11.

Eskenazi B, Wilson-Rich N, Starks P . A Darwinian approach to Huntington's disease: subtle health benefits of a neurological disorder. Med Hypotheses. 2007; 69(6):1183-9. DOI: 10.1016/j.mehy.2007.02.046. View

12.

Abada Y, Nguyen H, Schreiber R, Ellenbroek B . Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease. PLoS One. 2013; 8(7):e68584. PMC: 3708912. DOI: 10.1371/journal.pone.0068584. View

13.

Will T, Proano S, Thomas A, Kunz L, Thompson K, Ginnari L . Problems and Progress regarding Sex Bias and Omission in Neuroscience Research. eNeuro. 2017; 4(6). PMC: 5677705. DOI: 10.1523/ENEURO.0278-17.2017. View

14.

Kantor O, Temel Y, Holzmann C, Raber K, Nguyen H, Cao C . Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiol Dis. 2006; 22(3):538-47. DOI: 10.1016/j.nbd.2005.12.014. View

15.

Shansky R, Woolley C . Considering Sex as a Biological Variable Will Be Valuable for Neuroscience Research. J Neurosci. 2016; 36(47):11817-11822. PMC: 5125240. DOI: 10.1523/JNEUROSCI.1390-16.2016. View

16.

Hohn S, Dallerac G, Faure A, Urbach Y, Nguyen H, Riess O . Behavioral and in vivo electrophysiological evidence for presymptomatic alteration of prefrontostriatal processing in the transgenic rat model for huntington disease. J Neurosci. 2011; 31(24):8986-97. PMC: 6622938. DOI: 10.1523/JNEUROSCI.1238-11.2011. View

17.

Kaviani H, Gray J, Checkley S, Raven P, Wilson G, Kumari V . Affective modulation of the startle response in depression: influence of the severity of depression, anhedonia, and anxiety. J Affect Disord. 2004; 83(1):21-31. DOI: 10.1016/j.jad.2004.04.007. View

18.

Jiang A, Handley R, Lehnert K, Snell R . From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research. Int J Mol Sci. 2023; 24(16). PMC: 10455900. DOI: 10.3390/ijms241613021. View

19.

Vandeputte C, Taymans J, Casteels C, Coun F, Ni Y, Van Laere K . Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci. 2010; 11:92. PMC: 2924851. DOI: 10.1186/1471-2202-11-92. View

20.

Radovanovic S, Vodopic S, Stankovic I, Dragasevic-Miskovic N, Kostic V . Spatiotemporal gait characteristics of Huntington's disease during dual-task walking. Int J Neurosci. 2019; 130(2):136-143. DOI: 10.1080/00207454.2019.1667781. View